SynthesisCardiovascular and interventional radiology2026
Uterine Artery Embolization Using Gelatin Sponge Particles in Patients with Symptomatic Uterine Fibroids: A Systematic Review and Meta-Analysis.
Synthesis in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the efficacy and safety of uterine artery embolization (UAE) using gelatin sponge (GS) particles through a systematic review and meta-analysis. MATERIALS AND
methodsPubMed, Embase, Scopus, and Google Scholar were searched from inception to April 2024. Prospective and retrospective nonrandomized studies using GS particles for UAE in leiomyoma patients were included. Outcomes included dominant leiomyoma volume reduction and improvement in menorrhagia, dysmenorrhea, and bulk-related symptoms.
resultsSix studies with 429 participants were included. Three out of six studies compared GS to another embolic agent. Mean dominant leiomyoma volume reduction was 42.17% at 3 months (95% CI 33.65-50.68%), 53.37% at 6 months (95% CI 47.89-58.86%), and 58.71% at 12 months (95% CI 47.38-70.04%). Menorrhagia improved in 88% (95% CI 85-91%) at 3 months, 95% at 6 months (95% CI 70-100%), and 98% at 12 months (95% CI 92-100%). Dysmenorrhea improved in 90% at 3 months (95% CI 53-100%), 96% at 6 months (95% CI 66-100%), and 89% at 12 months (95% CI 61-100%). Bulk-related symptoms improved in 90% at 3 months (95% CI 74-99%) and 99% at 6 (95% CI 92-100%) and at 12 months (95% CI 95-100%). Amenorrhea was the most common adverse event. Other adverse events included deep venous thrombosis, groin hematomas, fibroid passage, symptom recurrence, anemia, postembolization syndrome, and elevated liver enzymes.
conclusionUAE using GS particles is a potentially effective treatment option for managing uterine leiomyoma. It reduces leiomyoma volume and improves menorrhagia, dysmenorrhea, and bulk-related symptoms. LEVEL OF EVIDENCE: Level 2a, Systematic Review & Meta-Analysis of Cohort Studies.
Indexed as
Identifiers
41805970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.